Pharmaceutical company BioInvent has published results from the first clinical Phase 1 study of the drug candidate BI-1808 in the scientific journal Clinical Cancer Research. The study included 24 patients with advanced solid tumors and showed a favorable safety profile as well as preliminary signals of antitumor activity.
Tumor reduction was observed in two of 21 evaluable patients. One patient with GIST achieved a partial response that lasted for more than two years. No dose-limiting toxicities or treatment-related adverse events above Grade 2 were reported.
The results support the continued development of BI-1808, with the 1,000 mg dose every three weeks being evaluated in Phase 2a studies.
